1. main-0273
Diabetes Herbal Medicine BLOCKBUSTER Formulation Of 16 Anti Diabetic Herbs
51-60 of 9000 51. -May 2, 2007 Higher dose Advair questioned by FDA panel A U. S. panel says there is not
enough evidence to show that higher doses of Advair help chronic obstructive pulmonary disease patients live
longer. GlaxoSmithKline is asking the Food and Drug Administration to approve higher dose of Advair to treat
patients with chronic obstructive pulmonary disease, or COPD, The Wall Street Journal said Wednesday. One
study submitted to the FDA panel showed a 2. 6 percent improvement in survival over three years among patients
receiving Advair. The...... . wire (USA)-July 21, 2006 Biopsy Study Shows Combination of Long-Acting Beta2-
Agonist and Low Steroid Dose in Advair Diskus(R) 100/50mcg Maintains Control of Airway Inflammation, Study
Supports National Institute of Health Guidelines for the Diagnosis and Management of Asthma PRNewswire--The
largest biopsy study conducted to date demonstrates that a lower dose of an inhaled corticosteroid (ICS) with the
addition of a long acting beta2-agonist (LABA) is as effective in maintaining control of airway inflammation as a
medium-dose ICS alone in patients with moderate asthma. The study, published in the July issue of the Journal of
Allergy and Clinical Immunology (JACI), compared Advair Diskus (fluticasone propionate and salmeterol) 100/50
mcg with fluticasone...... . (USA)-December 28, 2007 GlaxoSmithKline Tests Show Advair Edge Over Pfizer's
Spiriva In Treating COPD December 28, 2007 ( ) GlaxoSmithKline Plc (NYSE: GSK) said that clinical trial results
showed its top-seller Advair had an edge over Pfizer Inc. 's (NYSE: PFE) rival product Spiriva in treating patients
with the lung disease COPD. Glaxo said that a two-year study of 1, 300 patients found both drugs had a similar
impact on rate of exacerbations, but people treated with Advair gained a significant improvement in health status
and greater survival benefit than...... . (USA)-July 21, 2006 Biopsy Study Shows Combination of Long-Acting Beta2-
Agonist and Low Steroid Dose in Advair Diskus(R) 100/50mcg Maintains Control of Airway Inflammation, Study
Supports National Institute of Health Guidelines for the Diagnosis and Management of Asthma The largest biopsy
study conducted to date demonstrates that a lower dose of an inhaled corticosteroid (ICS) with the addition of a
long acting beta2-agonist (LABA) is as effective in maintaining control of airway inflammation as a medium-dose
ICS alone in patients with moderate asthma. The study, published in the July issue of the Journal of Allergy and
Clinical Immunology (JACI), compared Advair Diskus (fluticasone propionate and salmeterol) 100/50 mcg with
fluticasone...... . Nuevo Herald, El (Miami, FL)-October 28, 2005 LAS VENTAS DE ADVAIR DISPARAN UN 20%
LAS GANANCIAS DE GLAXO GlaxoSmithKline Plc, el mayor fabricante de medicamentos de Europa, dijo que
sus ganancias del tercer trimestre subieron 20 por ciento por las ventas del medicamento para el asma Advair. La
empresa londinense podría buscar socios para aumentar la producción de su tratamiento para la gripe, Relenza.
El ingreso neto subió a 1, 210 millones de libras ($2, 160 millones) o 21. 1 peniques por acción, desde 1, 000
millones de libras, o 17. 6 peniques, en el mismo periodo un año antes, dijo Glaxo...... . -December 11, 2008 FDA
advisers: restrict some asthma drugs Government health advisers recommended restrictions Thursday on some
long-acting asthma drugs, although not Advair, a top-selling medication. Outside experts advising the Food and
Drug Administration said Foradil and Serevent no longer should be used for asthma. But they said the benefits of
the more widely used Advair and Symbicort clearly outweigh the risks. Each contains an ingredient that relaxes
muscles around stressed airways. But that may mask symptoms that can trigger...... . wire (USA)-December 1,
2008 Advair's Patient Share in Newly Diagnosed Asthma Patients is Declining, Surveyed Physicians Will Continue
to Use Singulair Regardless of March 2008 Suicidality Claim, According to a New Report from Decision
Resources PRNewswire--Decision Resources, one of the world's leading research and advisory firms focusing on
pharmaceutical and healthcare issues, finds that patient share for GlaxoSmithKline's Advair is declining in all lines
of therapy for newly diagnosed asthma patients. The new report entitled Treatment Algorithms in Asthma shows a
reduction in Advair use in first-, second-and third-lines of therapy to 12. 2 percent, 13. 6 percent, and 14. 6 percent,
respectively when...... . Datamonitor-August 9, 2007 FDA rejects higher dose of GSK's Advair GlaxoSmithKline has
said that the FDA has declined to approve its supplemental drug application for the 500/50 strength of Advair
Diskus in the treatment of patients with chronic obstructive pulmonary disease. The FDA questioned how Advair
500/50 compared to the currently approved 250/50 strength in order to allow for appropriate dosing
recommendations. GSK says it will be meeting with the FDA to discuss this request in more detail and determine
next steps, including discussion of...... . , The (NC)-March 7, 2006 ADVAIR AND SEREVENT TO GET NEW
WARNINGS The asthma medication Advair and a related drug Serevent will bear stronger warnings of an
increased risk of death associated with one ingredient. Advair is GlaxoSmithKline's best-selling product, and
Serevent is another of the British company's drugs. The updated warnings on both drugs caution that salmeterol
may increase the risk of asthma-related death. Advair should be used only by patients when other asthma drugs,
such as low-to medium-dose inhaled...... . (KY)-December 6, 2008 Risks of new asthma drugs vary, FDA studies
find, fewer complications seen with advair WASHINGTON-The blockbuster asthma drug Advair does not appear to
have an increased risk of serious respiratory complications seen with similar new medicines, federal health
officials said Friday. But a less widely used medication, Serevent, had a significantly higher rate of complications
when compared to older treatments, the Food and Drug Administration said. Both drugs are made by the same
company, GlaxoSmithKline. FDA safety reviewers are recommending that Serevent no longer be......
Diabetes Herbal Medicine BLOCKBUSTER Formulation Of 16 Anti Diabetic Herbs